Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antibiotics for Appendicitis – Yes and No

By Drug Discovery Trends Editor | March 21, 2016

Using antibiotics as the primary treatment for mild appendicitis does not increase the risk for complications at least in the first year. But other considerations must also be taken into account, say researchers from the University of Helsinki.

Surgery has been the standard treatment for appendicitis for more than a century. Millions of appendectomies are performed annually in the world, more than 300,000 in the US alone. Studies have been carried out over the years to determine whether non-perforated appendicitis could be treated with antibiotics instead, but despite research results suggesting this, the choice of treatment remains largely unchanged.

An international collaboration group, including researchers from the University of Helsinki and McMaster University, analyzed five randomized controlled trials comparing the use of antibiotics and appendectomy to treat appendicitis. The trials included in the meta-analysis encompassed a total of 1,116 patients. The results were published in the British Journal of Surgery on 17 March, 2016.

According to the meta-analysis, roughly the same number of serious complications were found in the two groups: in 5 percent of the cases in the antibiotics group and 8 percent in the appendectomy group (pooled risk difference: – 3 percent). In the antibiotics group, 8 percent of the patients underwent an appendectomy within one month, and appendicitis recurred in 23 percent of the cases during the twelve-month follow-up.

“The studies did not provide a high quality evidence for complications, but according to best evidence available, using antibiotics as the primary treatment for mild appendicitis does not lead to more complications in the first twelve months of follow-up,” summarizes consultant gastrointestinal surgeon Ville Sallinen.

“Used as the primary treatment, antibiotics reduced the number of surgeries by 92 percent within the first month of diagnosis,” said adjunct professor Kari Tikkinen. “However, this choice of treatment meant that appendicitis recurred in 23 out of 100 patients within one year. Moreover, no long-term follow-up exists for now.”

Tikkinen and Sallinen, both from Helsinki University Hospital (Finland), point out that antibiotics can be used as the first-stage treatment for mild appendicitis, but that it is unclear how many of those treated with antibiotiocs first avoid surgery in the long term. Sallinen also mentions the increasingly more common resistance to antibiotics: “Would a change in treatment preferences and an increased use of antibiotics further boost this negative trend?”

To initiate antibiotics treatment, the diagnosis must be confirmed by a CT scan, which exposes the patient to radiation. “A diagnosis must always be made in emergency surgical care. The treatment must not be chosen based on suspicion alone,” Sallinen said.

Based on available evidence, the choice between surgery and antibiotics as treatment for mild appendicitis is a value and preference sensitive decision. Do we primarily want to prevent the appendicitis from recurring or do we want to avoid surgery if it is not possibly necessary? “In medicine and surgery, treatment choices are increasingly based on shared decision-making, where patients and care providers make decisions together. I expect that this will also increasing apply to treatment of mild appendicitis,” said Tikkinen.

Source: University of Helsinki


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50